CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-20 | Oren Ilan Director | Grant or award | +1,164 | 119,552 | ||
| 2026-01-20 | Oren Ilan Director | Shares withheld for taxes | −124 | $22.98 | $3K | 119,428 |
| 2026-01-20 | Epperly Melissa B, Director | Grant or award | +815 | 57,719 | ||
| 2026-01-20 | Epperly Melissa B, Director | Shares withheld for taxes | −54 | $22.98 | $1K | 57,665 |
| 2026-01-12 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,854,597 |
| 2026-01-12 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $21.92 | $4.4M | 1,654,597 |
| 2026-01-12 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 5,244,834 | ||
| 2025-12-31 | Sukhatme Mayukh President & CIO | Option exercise | +2,449,877 | $12.68 | $31.1M | 21,286,424 |
| 2025-12-31 | Sukhatme Mayukh President & CIO | Sale | −1,018,995 | $21.71 | $22.1M | 20,267,429 |
| 2025-12-31 | Sukhatme Mayukh President & CIO | Other disposition | −1,430,882 | $21.71 | $31.1M | 18,836,547 |
| 2025-12-31 | Sukhatme Mayukh President & CIO | Option exercise · Stock Option (Right to Buy) | −2,449,877 | 95,718 | ||
| 2025-12-29 | Sukhatme Mayukh President & CIO | Option exercise | +748,358 | $12.68 | $9.5M | 19,584,905 |
| 2025-12-29 | Sukhatme Mayukh President & CIO | Sale | −311,873 | $21.74 | $6.8M | 19,273,032 |
| 2025-12-29 | Sukhatme Mayukh President & CIO | Other disposition | −436,485 | $21.74 | $9.5M | 18,836,547 |
| 2025-12-29 | Sukhatme Mayukh President & CIO | Option exercise · Stock Option (Right to Buy) | −748,358 | 555,840 | ||
| 2025-12-24 | Torti Frank President and Vant Chair | Other disposition | −64,891 | $22.47 | $1.5M | 13,847,036 |
| 2025-12-24 | Torti Frank President and Vant Chair | Gift | −110,489 | 13,736,547 | ||
| 2025-12-24 | Venker Eric President & Immunovant CEO | Option exercise | +117,848 | $3.85 | $454K | 1,729,597 |
| 2025-12-24 | Venker Eric President & Immunovant CEO | Sale | −75,000 | $22.53 | $1.7M | 1,654,597 |
| 2025-12-24 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) | −117,848 | 5,444,834 |
Page 12 of 29 · 570 trades